Is Clio Cosmetics profitable in 2026?

Yes but shrinking: Clio Cosmetics posted FY2025 net income of KRW 13.56 billion, down 51.33% year-over-year, on consolidated revenue of KRW 328.90 billion, itself down 6.39% from FY2024, as of a 2026-07-12 report.

Is Clio Cosmetics losing market share?

Yes. Clio has logged multiple consecutive quarters of revenue decline through Q1 2026 (-4.84% y/y), while North America sales fell 27-36% across Q3 2024 to Q1 2025 and peer APR grew +111% in FY2025, per cartech.nate.com data.

Who owns Clio Cosmetics?

Clio Cosmetics (KOSDAQ:237880) is a publicly traded South Korean company. Major shareholder Hong Myeong-ha held 12.54% (2,265,688 shares) as of March 27, 2026 after continued on-market buying, per cartech.nate.com.

Could AI replace Clio Cosmetics?

Not the manufacturing or brand IP, but AI-driven D2C marketing is where rivals like APR are outpacing Clio. Clio's shade-matching, content creation, and forecasting functions are exposed; no evidence found of Clio itself deploying AI in operations as of 2026.

Who is Clio Cosmetics' biggest competitor?

APR (maker of Medicube) is the sharpest threat, posting FY2025 revenue of KRW 1.5273 trillion, up 111% year-over-year, driven by US expansion, versus Clio's North America revenue falling roughly 27-33% in the same period, per cartech.nate.com, 2026-02-09.

Why is Clio Cosmetics stock declining?

Weak North America sales and margin compression: Hyundai Motor Securities cut its Clio target price from KRW 47,000 to 25,000 in February 2025, then to KRW 18,000 in August 2025, citing intensified US and domestic competition.

Consumer brands · South Korea

Clio Cosmetics Co., Ltd.

clio.co.kr ↗

South Korean makeup brand known for Clio and Peripera, sold in Sephora, CVS, and Amazon.

Losing its protection

Assessed 26 July 2026 · Evidence as of 26 July 2026

The structural protection is eroding.

On the recordSince 26 July 2026 · Checkable from Q3 2026 · Every call on the record Checkpoint: Q2/Q3 2026 earnings, testing whether Amazon cushion line and Peripera tint launch reverse North America decline

The call

Clio still turns a profit and sits on real shelf space, but four straight quarters of decline show peers like APR out-executing it in the same stores.

Clio makes makeup and beauty products sold in stores and online, mostly in Korea and parts of Asia. Bigger companies like AmorePacific and LG can make the same products just as well, and a rival called APR is already growing much faster in the US while Clio's sales keep dropping. The one thing that could save it is whether its new products on Amazon and other online stores starting in early 2025 can actually stop the slide in sales, but three straight quarters of losses suggest that is unlikely.

Why

AI pressure: None apparent. AI is not the thing eating this business, indie brands and shelf competition are. Could AI do the core job? Only partly.

Bigger players: APR (Medicube), AmorePacific, LG H&H. APR grew North America sales +111% while Clio's North America revenue fell 27-33% for three straight quarters. Could a giant copy it? Yes, easily.

What protects it. Established retail placement at Sephora, CVS, and Amazon plus a 30 year brand history and a new Japan distribution network of 15,000 plus stores.

What would change this call

Clio's Q2/Q3 2026 North America revenue line in earnings release. Shows whether Amazon cushion and Peripera tint launches reverse the NA collapse or confirm continued loss.
Further analyst target-price cuts on Clio stock beyond KRW 18K. Would confirm analysts see no near-term recovery from current deterioration.
APR/Medicube reported US sales or shelf-share figures in Amazon/Sephora over next two quarters. Shows whether the peer is continuing to take mid-tier K-beauty share from Clio.

Key numbers

North America revenue down 33% in Q1 2025 (2025-07-22)
FY2025 net income fell 51.33% to KRW 13.56B (2026-06-25)
Market cap down 28-40% YoY as of July 2026 (2026-07-09)

Named risks

Multiple consecutive quarters of revenue and profit decline through Q1 2026. Severity: high
North America revenue fell 27-36% across three separate quarters in 2024-2025. Severity: high
No structural moat separating Clio from larger incumbents AmorePacific and LG H&H. Severity: high
Two analyst target-price cuts in 2025 signal deteriorating market confidence. Severity: medium
Single-sourced headcount and conflicting IPO-date data raise data-quality concerns. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
APR (Medicube)	losing to	FY2025 revenue +111% YoY to KRW 1.5273 trillion vs Clio's decline, as of 2026-02-09
AmorePacific	losing to	FY2025 revenue +8.5% YoY to KRW 4.6232 trillion, no structural barrier to entering Clio's segments
LG Household & Health Care	contesting	Larger incumbent with no structural prohibition from Clio's cosmetics segments, per 2026-02-09 report
Silicon2 (distributor)	gaining on	FY2025 revenue +61.9% YoY to ~KRW 1.1196 trillion, as of 2026-02-26
Indie K-beauty brands	gaining on	Cited as driving Clio's North America share loss, per 2025-07-22 report

Questions people ask

Is Clio Cosmetics profitable in 2026?: Yes but shrinking: Clio Cosmetics posted FY2025 net income of KRW 13.56 billion, down 51.33% year-over-year, on consolidated revenue of KRW 328.90 billion, itself down 6.39% from FY2024, as of a 2026-07-12 report.
Is Clio Cosmetics losing market share?: Yes. Clio has logged multiple consecutive quarters of revenue decline through Q1 2026 (-4.84% y/y), while North America sales fell 27-36% across Q3 2024 to Q1 2025 and peer APR grew +111% in FY2025, per cartech.nate.com data.
Who owns Clio Cosmetics?: Clio Cosmetics (KOSDAQ:237880) is a publicly traded South Korean company. Major shareholder Hong Myeong-ha held 12.54% (2,265,688 shares) as of March 27, 2026 after continued on-market buying, per cartech.nate.com.
Could AI replace Clio Cosmetics?: Not the manufacturing or brand IP, but AI-driven D2C marketing is where rivals like APR are outpacing Clio. Clio's shade-matching, content creation, and forecasting functions are exposed; no evidence found of Clio itself deploying AI in operations as of 2026.
Who is Clio Cosmetics' biggest competitor?: APR (maker of Medicube) is the sharpest threat, posting FY2025 revenue of KRW 1.5273 trillion, up 111% year-over-year, driven by US expansion, versus Clio's North America revenue falling roughly 27-33% in the same period, per cartech.nate.com, 2026-02-09.
Why is Clio Cosmetics stock declining?: Weak North America sales and margin compression: Hyundai Motor Securities cut its Clio target price from KRW 47,000 to 25,000 in February 2025, then to KRW 18,000 in August 2025, citing intensified US and domestic competition.

Timeline

2026-07-12FY2025 revenue reported at KRW 328.90B, down 6.39% year-over-year
2026-07-09Market cap KRW 165-203B, down 28-40% year-over-year
2026-06-25FY2025 net income fell 51.33% to KRW 13.56B; headcount reported at 333
2026-03-27Major shareholder Hong Myeong-ha's stake rises to 12.54% via on-market buying
2025-08-29Hyundai Motor Securities cuts Clio target price from KRW 25,000 to 18,000
2025-07-22Report details North America revenue collapse of 27-33% across three quarters
2025-05Peripera North America-exclusive tint launched to counter NA sales slump
2025-02-24Hyundai Motor Securities cuts Clio target price from KRW 47,000 to 25,000
2025-01North America-exclusive 20-shade cushion foundation launched on Amazon
2024-04-30Clio acquires Japanese distributors Doowon and Kiwami for KRW 8.3B

Revision history

26 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

PVH VF Kering